| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -22,241 | -18,730 |
| Depreciation expense | 201 | 135 |
| Stock-based compensation expense | 2,542 | 2,481 |
| Non-cash lease expense | 818 | 539 |
| Non-cash interest and other expense, net | 77 | 76 |
| Prepaid expenses and other assets | -582 | -339 |
| Accounts payable | -1,528 | 2,266 |
| Accrued expenses and other liabilities | -3,032 | -3,166 |
| Interest payable | -59 | -59 |
| Operating lease liabilities | -606 | -348 |
| Cash used in operating activities | -23,246 | -16,467 |
| Purchase of property and equipment | 0 | 0 |
| Cash used in investing activities | 0 | 0 |
| Proceeds from the issuance of common stock, net of issuance costs | 5,013 | 5,013 |
| Proceeds from the issuance of pre-funded warrants, net of issuance costs | 1,858 | 1,858 |
| Repayment of loan | 6,426 | 6,426 |
| Proceeds from the issuance of common stock under equity plan awards | 47 | 34 |
| Cash provided by financing activities | 492 | 479 |
| Net decrease in cash, cash equivalents and restricted cash | -22,754 | -15,988 |
| Cash and cash equivalents at beginning of period | 30,711 | - |
| Cash and cash equivalents at end of period | 7,957 | - |
Tempest Therapeutics, Inc. (TPST)
Tempest Therapeutics, Inc. (TPST)